C-C Chemokine Receptor Type 5 - Pipeline Review, H1 2020
C-C Chemokine Receptor Type 5 - Pipeline Review, H1 2020
SUMMARY
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 15 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report C-C Chemokine Receptor Type 5 – Pipeline Review, H1 2020, outlays comprehensive information on the C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) – C-C chemokine receptor type 5 (CCR5) also known as CD195, is a surface protein located on the plasma membrane of white blood cells and is encoded by CCR5 gene. This receptor binds and responds to a variety of chemokines (CCL3, CCL4, CCL5, CCL3L1). This protein is expressed by T cells and macrophages, and is known to be an important co-receptor for macrophage-tropic virus, including HIV, to enter host cells. It plays a role in granulocyte lineage proliferation and differentiation. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 3, 2, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.
Report covers products from therapy areas Infectious Disease, Oncology, Gastrointestinal, Central Nervous System, Respiratory, Cardiovascular, Hormonal Disorders, Immunology and Musculoskeletal Disorders which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Metastatic Colorectal Cancer, Non-Alcoholic Steatohepatitis (NASH), Chronic Obstructive Pulmonary Disease (COPD), Liver Fibrosis, Multiple Sclerosis, Autoimmune Hepatitis, Bladder Cancer, Bone Metastasis, Colon Carcinoma, Colorectal Cancer, Coronavirus Disease 2019 (COVID-19), Crohn's Disease (Regional Enteritis), Gastric Cancer, Glioblastoma Multiforme (GBM), Graft Versus Host Disease (GVHD), Graves Diseases, Hashimoto Thyroiditis, Hepatocellular Carcinoma, Inflammatory Bowel Disease, Liver Cancer, Lung Cancer, Melanoma, Metastatic Breast Cancer, Metastatic Pancreatic Cancer, Myasthenia Gravis, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Polymyositis, Primary Sclerosing Cholangitis, Primary Sjogren's Syndrome, Prostate Cancer, Psoriasis, Testicular Cancer, Throat Cancer, Triple-Negative Breast Cancer (TNBC), Uterine Cancer and Vasculitis.
Furthermore, this report also reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 15 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report C-C Chemokine Receptor Type 5 – Pipeline Review, H1 2020, outlays comprehensive information on the C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) – C-C chemokine receptor type 5 (CCR5) also known as CD195, is a surface protein located on the plasma membrane of white blood cells and is encoded by CCR5 gene. This receptor binds and responds to a variety of chemokines (CCL3, CCL4, CCL5, CCL3L1). This protein is expressed by T cells and macrophages, and is known to be an important co-receptor for macrophage-tropic virus, including HIV, to enter host cells. It plays a role in granulocyte lineage proliferation and differentiation. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 3, 2, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.
Report covers products from therapy areas Infectious Disease, Oncology, Gastrointestinal, Central Nervous System, Respiratory, Cardiovascular, Hormonal Disorders, Immunology and Musculoskeletal Disorders which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Metastatic Colorectal Cancer, Non-Alcoholic Steatohepatitis (NASH), Chronic Obstructive Pulmonary Disease (COPD), Liver Fibrosis, Multiple Sclerosis, Autoimmune Hepatitis, Bladder Cancer, Bone Metastasis, Colon Carcinoma, Colorectal Cancer, Coronavirus Disease 2019 (COVID-19), Crohn's Disease (Regional Enteritis), Gastric Cancer, Glioblastoma Multiforme (GBM), Graft Versus Host Disease (GVHD), Graves Diseases, Hashimoto Thyroiditis, Hepatocellular Carcinoma, Inflammatory Bowel Disease, Liver Cancer, Lung Cancer, Melanoma, Metastatic Breast Cancer, Metastatic Pancreatic Cancer, Myasthenia Gravis, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Polymyositis, Primary Sclerosing Cholangitis, Primary Sjogren's Syndrome, Prostate Cancer, Psoriasis, Testicular Cancer, Throat Cancer, Triple-Negative Breast Cancer (TNBC), Uterine Cancer and Vasculitis.
Furthermore, this report also reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)
- The report reviews C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics and enlists all their major and minor projects
- The report assesses C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Overview
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Development
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Assessment
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Companies Involved in Therapeutics Development
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Drug Profiles
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Dormant Products
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Discontinued Products
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Product Development Milestones
Appendix
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Overview
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Development
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Assessment
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Companies Involved in Therapeutics Development
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Drug Profiles
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Dormant Products
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Discontinued Products
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Allergan Plc, H1 2020
Pipeline by American Gene Technologies International Inc, H1 2020
Pipeline by Auritec Pharmaceuticals Inc, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by Cytodyn Inc, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by Orion Biotechnology Canada Ltd, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Allergan Plc, H1 2020
Pipeline by American Gene Technologies International Inc, H1 2020
Pipeline by Auritec Pharmaceuticals Inc, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by Cytodyn Inc, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by Orion Biotechnology Canada Ltd, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
Allergan Plc
American Gene Technologies International Inc
Auritec Pharmaceuticals Inc
Bristol-Myers Squibb Co
Cytodyn Inc
Merck & Co Inc
Novartis AG
Orion Biotechnology Canada Ltd
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
Allergan Plc
American Gene Technologies International Inc
Auritec Pharmaceuticals Inc
Bristol-Myers Squibb Co
Cytodyn Inc
Merck & Co Inc
Novartis AG
Orion Biotechnology Canada Ltd
